Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.1K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

651
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
651
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

793
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
793
Peptic Ulcer01:27

Peptic Ulcer

31
Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the...
31
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.7K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.7K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.5K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic variants associated with clinical characteristics and atopies in eosinophilic esophagitis.

The journal of allergy and clinical immunology. Global·2026
Same author

Non-celiac gluten sensitivity: balance between hype and hard reality.

Medicina clinica·2026
Same author

Dupilumab for Eosinophilic Esophagitis in Adolescents and Adults: Real-World Outcomes Across Different Dosing Regimens from the EoE CONNECT Registry.

The American journal of gastroenterology·2026
Same author

Peranal Endoscopic Myectomy for Lower Rectal Lesions with Severe Fibrosis: A Retrospective Study.

Digestive diseases and sciences·2026
Same author

Long-Term Loss of Response to Proton Pump Inhibitors Is Uncommon in Adult Eosinophilic Esophagitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Safety and Efficacy of Oral Tacrolimus Induction Therapy in Elderly Patients with Ulcerative Colitis: A Subanalysis of a Large Multicenter Retrospective Cohort Study.

Gerontology·2026

Related Experiment Video

Updated: Apr 4, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

894

Practical Aspects in Choosing a Helicobacter pylori Therapy.

Javier Molina-Infante1, Akiko Shiotani2

  • 1Department of Gastroenterology, Hospital San Pedro de Alcantara, C/Pablo Naranjo s/n, Caceres 10003, Spain.

Gastroenterology Clinics of North America
|August 29, 2015
PubMed
Summary

Effective Helicobacter pylori eradication requires tailored antimicrobial therapy. Current standard triple therapy is often insufficient, necessitating personalized treatment based on bacterial susceptibility and patient history for optimal cure rates.

Keywords:
BismuthConcomitantEradicationHelicobacter pyloriQuadrupleResistanceTherapyTriple

More Related Videos

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.7K
Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
04:56

Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis

Published on: May 16, 2025

1.4K

Related Experiment Videos

Last Updated: Apr 4, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

894
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.7K
Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
04:56

Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis

Published on: May 16, 2025

1.4K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Antimicrobial therapy for Helicobacter pylori infection traditionally aimed for cure rates exceeding 90%-95%.
  • Standard triple therapy regimens are no longer consistently achieving these high efficacy rates globally.
  • Evolving antibiotic resistance patterns necessitate a re-evaluation of H. pylori treatment strategies.

Purpose of the Study:

  • To review current evidence on Helicobacter pylori eradication therapies.
  • To identify factors influencing the success of antimicrobial treatment for H. pylori infection.
  • To recommend updated first-line and rescue treatment regimens.

Main Methods:

  • Literature review of clinical studies and guidelines on H. pylori eradication.
  • Analysis of factors impacting treatment efficacy, including bacterial susceptibility and prior antibiotic exposure.
  • Evaluation of current recommended first-line and salvage therapies.

Main Results:

  • Standard triple therapy's efficacy has declined, failing to meet expected cure rates.
  • Key predictors of successful eradication include H. pylori susceptibility, patient's prior antibiotic history, and local resistance data.
  • Preferred first-line options include 14-day bismuth quadruple and 14-day concomitant quadruple therapy.

Conclusions:

  • Personalized antimicrobial therapy selection is crucial for achieving high H. pylori cure rates.
  • Treatment decisions should incorporate H. pylori susceptibility, patient history, and local resistance patterns.
  • Bismuth quadruple, fluoroquinolone-, furazolidone-, and rifabutin-based regimens show promise as rescue treatments.